CIK 0001279704 · Non-accelerated filer<br>Smaller reporting company
Cellectar Biosciences, Inc.
Sign in to watch- Ticker
- CLRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043321804
- Phone
- (608) 441-8120
- Business address
- 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
- Former names
- NOVELOS THERAPEUTICS, INC., COMMON HORIZONS INC
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Chief Business Officer bought 500 shares at $2.71 ($1,355)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Business Officer sold 13,000 shares at $1.18 ($15,397)
- 4 Open-market sale President and CEO sold 34,000 shares at $1.20 ($40,705)
- 4 Open-market sale Director sold 5,214 shares at $1.49 ($7,791)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award VP, Chief Financial Officer acquired 80,000 shares (grant or award)
- 4 Grant or award Sr. VP of Corp Dev & Ops acquired 80,000 shares (grant or award)
- 4 Grant or award President and CEO acquired 200,000 shares (grant or award)
- 4 Grant or award VP, Chief Medical Officer acquired 100,000 shares (grant or award)
Page 7 of 11 · 211 filings